Accessibility Statement Skip Navigation
  • Back to Global Sites
  • +972-77-2005042
  • Blog
  • Journalists
  • GDPR
  • Send a Release
PR Newswire: news distribution, targeting and monitoring
  • News
  • Products
  • Contact
  • Hamburger menu
  • PR Newswire: news distribution, targeting and monitoring
  • Send a Release
    • Telephone

    • +972-77-2005042 from 8 AM - 11 PM IL

    • Contact
    • Contact

      +972-77-2005042
      from 8 AM - 11 PM IL

Close menu
  • News
  • Products
  • Contact
    • Request More Information
    • Journalists
    • GDPR

    BioLineRx to Report Third Quarter 2026 Results on November 23, 2026

    BioLineRx Ltd. Logo

    News provided by

    BioLineRx Ltd.

    18 Nov, 2026, 16:00 IST

    Share this article

    Share this article


    Management to Hold Conference Call at 8:30 a.m. EST

    TEL AVIV, Israel, Nov. 18, 2026 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today announced that it will release its unaudited financial results for the third quarter ended September 30, 2026 on Monday, November 23, 2026, before the U.S. markets open.

    The Company will host a conference call at 8:30 a.m. EST featuring remarks by Philip Serlin, Chief Executive Officer.

    To access the conference call, please dial +1-888-407-2553 from the U.S. or +972-3-918-0685 internationally. A live webcast and a replay of the call can be accessed through the event page on the Company's website. Please allow extra time prior to the call to visit the site and download any necessary software to listen to the live broadcast. The call replay will be available approximately two hours after completion of the live conference call. A dial-in replay of the call will be available until November 25, 2026; please dial +1-888-295-2634 from the US or +972-3-925-5904 internationally.

    About BioLineRx

    BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX) is a biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases. The Company's lead development asset is GLIX1, a first-in-class, oral, small molecule targeting DNA damage response in glioblastoma and other solid tumors, for which a Phase 1/2a clinical trial has been initiated in the first quarter of 2026. GLIX1 is being developed under a collaboration with Hemispherian AS.

    The Company's first approved product, APHEXDA® (motixafortide), is indicated in the U.S. for stem cell mobilization for autologous transplantation in multiple myeloma, and is being commercialized by Ayrmid Ltd. (globally, except Asia) and Gloria Biosciences (in Asia). BioLineRx has retained the rights to develop motixafortide in solid tumors, including metastatic pancreatic cancer (PDAC), and has a Phase 2b PDAC trial currently ongoing under a collaboration with Columbia University.

    Learn more about who we are, what we do, and how we do it at www.biolinerx.com, or on LinkedIn.

    CONTACTS:

    United States
    Chuck Padala
    LifeSci Advisors, LLC
    [email protected]

    Israel
    Moran Meir
    LifeSci Advisors, LLC
    [email protected]

    SOURCE BioLineRx Ltd.

    Modal title

    Also from this source

    BioLineRx Enters into $5.6 Million Royalty Monetization Transaction with Soleus Capital

    BioLineRx Enters into $5.6 Million Royalty Monetization Transaction with Soleus Capital

    BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company pursuing life-changing therapies in oncology and rare...

    BioLineRx Reports Second Quarter 2026 Financial Results and Provides Corporate Update

    BioLineRx Reports Second Quarter 2026 Financial Results and Provides Corporate Update

    BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company pursuing life-changing therapies in oncology and rare...

    More Releases From This Source

    Contact PR Newswire

    • +972-77-2005042
      from 8 AM - 11 PM IL

    Global Sites

    • APAC
    • APAC - Traditional Chinese
    • Asia
    • Brazil
    • Canada
    • Czech
    • Denmark
    • Finland
    • France
    • Germany

     

    • India
    • Indonesia
    • Israel
    • Italy
    • Mexico
    • Middle East
    • Middle East - Arabic
    • Netherlands
    • Norway
    • Poland

     

    • Portugal
    • Russia
    • Slovakia
    • Spain
    • Sweden
    • United Kingdom
    • United States

    Do not sell or share my personal information:

    • Submit via [email protected] 
    • Call Privacy toll-free: 877-297-8921
    Global Sites
    • Asia
    • Brazil
    • Canada
    • Csezh
    • Denmark
    • Finland
    • France
    • Germany
    • India
    • Israel
    • Italie
    • Mexico
    • Middle East
    • Netherlands
    • Norway
    • Poland
    • Portugal
    • Russia
    • Slovakia
    • Spain
    • Sweden
    • United Kingdom
    • United States
    +972-77-2005042
    from 8 AM - 11 PM IL
    • Terms of Use
    • Privacy Policy
    • Information Security Policy
    • Site Map
    • Cookie Settings
    Copyright © 2026 Cision US Inc.